The Houston andrologist ties GLP-1 drugs to heart, kidney, liver, sleep and testosterone gains, citing an ENDO 2025 study where normal testosterone rose from 53% to 77%.
Recap by typeshit. Full story at BBN Times.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
Pannu points to over $8B in upfront FGF21 deals and 500+ assets in development, and says the commercial and clinical split is arriving unusually early.
Free Malaysia Today reports that price is holding back use of weight loss drugs in developing markets, where penetration rates remain low.
Loading…